75 related articles for article (PubMed ID: 20473854)
21. Differential MHC class II component expression in HPV-positive cervical cancer cells: implication for immune surveillance.
Zehbe I; Höhn H; Pilch H; Neukirch C; Freitag K; Maeurer MJ
Int J Cancer; 2005 Dec; 117(5):807-15. PubMed ID: 15981207
[TBL] [Abstract][Full Text] [Related]
22. Cervical carcinoma cells transfected with the CD80 gene elicit a primary cytotoxic T lymphocyte response specific for HPV 16 E7 antigens.
Kaufmann AM; Gissmann L; Schreckenberger C; Qiao L
Cancer Gene Ther; 1997; 4(6):377-82. PubMed ID: 9408608
[TBL] [Abstract][Full Text] [Related]
23. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter.
Welters MJ; de Jong A; van den Eeden SJ; van der Hulst JM; Kwappenberg KM; Hassane S; Franken KL; Drijfhout JW; Fleuren GJ; Kenter G; Melief CJ; Offringa R; van der Burg SH
Cancer Res; 2003 Feb; 63(3):636-41. PubMed ID: 12566307
[TBL] [Abstract][Full Text] [Related]
24. HPV genotypes predict survival benefits from concurrent chemotherapy and radiation therapy in advanced squamous cell carcinoma of the cervix.
Wang CC; Lai CH; Huang YT; Chao A; Chou HH; Hong JH
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e499-506. PubMed ID: 22889667
[TBL] [Abstract][Full Text] [Related]
25. Decreased frequency of HLA-DRB1 13 alleles in Frenchwomen with HPV-positive carcinoma of the cervix.
Sastre-Garau X; Loste MN; Vincent-Salomon A; Favre M; Mouret E; de la Rochefordiere A; Durand JC; Tartour E; Lepage V; Charron D
Int J Cancer; 1996 Jun; 69(3):159-64. PubMed ID: 8682580
[TBL] [Abstract][Full Text] [Related]
26. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
27. Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens.
van der Burg SH; Piersma SJ; de Jong A; van der Hulst JM; Kwappenberg KM; van den Hende M; Welters MJ; Van Rood JJ; Fleuren GJ; Melief CJ; Kenter GG; Offringa R
Proc Natl Acad Sci U S A; 2007 Jul; 104(29):12087-92. PubMed ID: 17615234
[TBL] [Abstract][Full Text] [Related]
28. Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens.
Youde SJ; Dunbar PR; Evans EM; Fiander AN; Borysiewicz LK; Cerundolo V; Man S
Cancer Res; 2000 Jan; 60(2):365-71. PubMed ID: 10667589
[TBL] [Abstract][Full Text] [Related]
29. Human leukocyte antigen class I/II alleles and development of human papillomavirus-related cervical neoplasia: results from a case-control study conducted in the United States.
Hildesheim A; Schiffman M; Scott DR; Marti D; Kissner T; Sherman ME; Glass AG; Manos MM; Lorincz AT; Kurman RJ; Buckland J; Rush BB; Carrington M
Cancer Epidemiol Biomarkers Prev; 1998 Nov; 7(11):1035-41. PubMed ID: 9829713
[TBL] [Abstract][Full Text] [Related]
30. Tumor-infiltrating CD14-positive myeloid cells and CD8-positive T-cells prolong survival in patients with cervical carcinoma.
de Vos van Steenwijk PJ; Ramwadhdoebe TH; Goedemans R; Doorduijn EM; van Ham JJ; Gorter A; van Hall T; Kuijjer ML; van Poelgeest MI; van der Burg SH; Jordanova ES
Int J Cancer; 2013 Dec; 133(12):2884-94. PubMed ID: 23740735
[TBL] [Abstract][Full Text] [Related]
31. Cervical carcinoma: human papillomavirus infection and HLA-associated risk factors in the Spanish population.
Montoya L; Saiz I; Rey G; Vela F; Clerici-Larradet N
Eur J Immunogenet; 1998 Oct; 25(5):329-37. PubMed ID: 9805655
[TBL] [Abstract][Full Text] [Related]
32. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG
Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058
[TBL] [Abstract][Full Text] [Related]
33. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients.
Fu J; Xu D; Liu Z; Shi M; Zhao P; Fu B; Zhang Z; Yang H; Zhang H; Zhou C; Yao J; Jin L; Wang H; Yang Y; Fu YX; Wang FS
Gastroenterology; 2007 Jun; 132(7):2328-39. PubMed ID: 17570208
[TBL] [Abstract][Full Text] [Related]
34. Disease-stage variance in functional CD4(+) T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes.
Warrino DE; Olson WC; Knapp WT; Scarrow MI; D'Ambrosio-Brennan LJ; Guido RS; Edwards RP; Kast WM; Storkus WJ
Clin Cancer Res; 2004 May; 10(10):3301-8. PubMed ID: 15161683
[TBL] [Abstract][Full Text] [Related]
35. Infiltrating T-cell markers in cervical carcinogenesis: a systematic review and meta-analysis.
Litwin TR; Irvin SR; Chornock RL; Sahasrabuddhe VV; Stanley M; Wentzensen N
Br J Cancer; 2021 Feb; 124(4):831-841. PubMed ID: 33257839
[TBL] [Abstract][Full Text] [Related]
36. T-cell receptor V and J usage paired with specific HLA alleles associates with distinct cervical cancer survival rates.
Roca AM; Chobrutskiy BI; Callahan BM; Blanck G
Hum Immunol; 2019 Apr; 80(4):237-242. PubMed ID: 30684568
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of multiple biologic parameters in cervical carcinoma: high macrophage infiltration in HPV-associated tumors.
Connor ME; Davidson SE; Stern PL; Arrand JR; West CM
Int J Gynecol Cancer; 1993 Mar; 3(2):103-109. PubMed ID: 11578329
[TBL] [Abstract][Full Text] [Related]
38. Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer.
Heusinkveld M; Goedemans R; Briet RJ; Gelderblom H; Nortier JW; Gorter A; Smit VT; Langeveld AP; Jansen JC; van der Burg SH
Int J Cancer; 2012 Jul; 131(2):E74-85. PubMed ID: 22020783
[TBL] [Abstract][Full Text] [Related]
39. CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend.
Kim KH; Greenfield WW; Cannon MJ; Coleman HN; Spencer HJ; Nakagawa M
Cancer Immunol Immunother; 2012 Jan; 61(1):63-70. PubMed ID: 21842207
[TBL] [Abstract][Full Text] [Related]
40. The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccination.
Mühlenbruch L; Abou-Kors T; Dubbelaar ML; Bichmann L; Kohlbacher O; Bens M; Thomas J; Ezić J; Kraus JM; Kestler HA; von Witzleben A; Mytilineos J; Fürst D; Engelhardt D; Doescher J; Greve J; Schuler PJ; Theodoraki MN; Brunner C; Hoffmann TK; Rammensee HG; Walz JS; Laban S
Br J Cancer; 2023 May; 128(9):1777-1787. PubMed ID: 36823366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
